Altimmune Inc
ALT
Company Profile
Business description
Altimmune Inc is a clinical-stage biopharmaceutical company focused on developing treatments for obesity, metabolic diseases, and liver diseases. Its product candidate, pemvidutide (formerly known as ALT-801), is a novel, investigational, peptide-based GLP-1/glucagon dual receptor agonist. Pemvidutide is currently in clinical development for obesity and metabolic-associated steatohepatitis (MASH). The company also plans to pursue additional indications for pemvidutide that leverage the differentiated clinical profile of pemvidutide.
Contact
910 Clopper Road
Suite 201S
GaithersburgMD20878
USAT: +1 240 654-1450
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
59
Altimmune Inc News & Analysis
stocks
2 companies poised to capitalize on the rise of GLP-1 drugs
Why Pfizer and Roche look like top choices for investors in the war to tip the scales.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,154.90 | 26.00 | -0.28% |
| CAC 40 | 8,219.40 | 42.76 | -0.52% |
| DAX 40 | 24,312.41 | 290.63 | -1.18% |
| Dow JONES (US) | 49,501.30 | 260.31 | 0.53% |
| FTSE 100 | 10,310.67 | 91.67 | -0.88% |
| HKSE | 26,885.24 | 37.92 | 0.14% |
| NASDAQ | 22,904.58 | 350.61 | -1.51% |
| Nikkei 225 | 53,818.04 | 475.32 | -0.88% |
| NZX 50 Index | 13,444.02 | 23.27 | -0.17% |
| S&P 500 | 6,882.72 | 0.00 | 0.00% |
| S&P/ASX 200 | 8,889.20 | 14.80 | -0.17% |
| SSE Composite Index | 4,075.92 | 26.29 | -0.64% |